Related Experiment Video

Updated: Aug 3, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

A DNA uptake-stimulating protein increases the antiproliferative effect of c-myb antisense oligonucleotide on

György Tóth1, József Schlammadinger, János Aradi

  • 1Department of Human Genetics, University of Debrecen, Medical and Health Science Center, Faculty of Medicine, Debrecen, Hungary.

Cell Biology International
|November 26, 2004
PubMed

Insights

A DNA uptake-stimulating factor (DUSF) enhances the antiproliferative effect of c-myb antisense oligonucleotide (ASO) in leukemia cells. DUSF boosts ASO uptake, significantly reducing c-myb protein expression and cell proliferation.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • Antisense oligonucleotides (ASOs) offer targeted therapeutic potential for cancer by inhibiting specific gene expression.
  • The efficacy of ASOs can be limited by cellular uptake efficiency.
  • The c-myb proto-oncogene is implicated in the proliferation of various leukemia cell lines.

Purpose of the Study:

  • To investigate the role of a DNA uptake-stimulating factor (DUSF) in enhancing the antiproliferative activity of c-myb antisense oligonucleotides (ASOs).
  • To determine if DUSF improves the cellular uptake and subsequent inhibition of c-myb protein expression by ASOs in leukemia cells.

Main Methods:

  • Treatment of HL-60 and MOLT4 leukemia cells with c-myb ASO in the presence or absence of DUSF.
  • Assessment of cell proliferation inhibition.
  • Quantification of cellular c-myb protein expression levels, particularly in the nucleus.

Main Results:

  • c-myb ASO significantly inhibited proliferation of HL-60 and MOLT4 cells only when DUSF was present; the effect was mild without DUSF.
  • DUSF alone, sense oligonucleotides, or the combination of sense oligonucleotides and DUSF showed no inhibitory effect.
  • Cellular c-myb protein expression was markedly reduced by c-myb ASO in the presence of DUSF, with near-complete disappearance from nuclei.

Conclusions:

  • DUSF effectively stimulates the in vitro uptake of c-myb ASO into leukemia cells.
  • DUSF augments the antiproliferative effect of c-myb ASO by enhancing its ability to decrease c-myb expression.
  • This study highlights DUSF as a potential enhancer for ASO-mediated cancer therapy.

More Related Videos

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays11:05

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...